Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $91,848.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 4,300 shares of the stock in a transaction dated Wednesday, December 31st. The shares were bought at an average cost of $21.36 per share, with a total value of $91,848.00. Following the completion of the purchase, the chief executive officer directly owned 5,599,402 shares of the company’s stock, valued at approximately $119,603,226.72. This trade represents a 0.08% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Snehal Patel also recently made the following trade(s):

• On Tuesday, December 30th, Snehal Patel purchased 2,900 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $21.73 per share, with a total value of $63,017.00.
• On Thursday, December 18th, Snehal Patel bought 4,100 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $12.62 per share, with a total value of $51,742.00.
• On Tuesday, November 25th, Snehal Patel purchased 4,600 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $8.37 per share, for a total transaction of $38,502.00.
• On Friday, November 7th, Snehal Patel acquired 10,600 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $8.43 per share, with a total value of $89,358.00.
• On Friday, October 31st, Snehal Patel acquired 2,300 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $9.26 per share, for a total transaction of $21,298.00.

Greenwich LifeSciences Price Performance

Shares of Greenwich LifeSciences stock opened at $19.47 on Monday. The stock has a market cap of $269.66 million, a PE ratio of -13.34 and a beta of 1.47. The firm has a fifty day moving average price of $11.10 and a 200 day moving average price of $10.95. Greenwich LifeSciences, Inc. has a 1 year low of $7.78 and a 1 year high of $30.82.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.30). As a group, equities analysts expect that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on GLSI shares. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. HC Wainwright upped their price target on Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $47.50.

Hedge Funds Weigh In On Greenwich LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its stake in Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares during the last quarter. Strs Ohio purchased a new stake in shares of Greenwich LifeSciences during the first quarter worth $177,000. Rhumbline Advisers raised its position in shares of Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after buying an additional 3,168 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Greenwich LifeSciences by 1.4% in the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after buying an additional 1,972 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Greenwich LifeSciences in the second quarter worth about $25,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences News Summary

Here are the key news stories impacting Greenwich LifeSciences this week:

• Positive Sentiment: HC Wainwright raised its price target to $50 (from $39) and continues to carry a “Buy” rating, a bullish analyst signal that can support longer-term upside. Greenwich LifeSciences price target raised to $50 from $39 at HC Wainwright
• Positive Sentiment: Company publicity: Greenwich announced a claimed new milestone in breast cancer prevention — a potentially material clinical/strategic development that could drive future revenue or partnership interest if substantiated. New milestone in breast cancer prevention claimed by Greenwich
• Positive Sentiment: Insider buy: CEO Snehal Patel purchased 2,900 shares at about $21.73 (SEC filing), a small additional personal stake that investors often view as a vote of confidence by management. SEC insider transaction filing
• Negative Sentiment: Continued expected losses: HC Wainwright’s detailed estimates project quarterly EPS of about ($0.30–$0.31) across 2025–2026 and FY2026 EPS of ($1.24), highlighting that the company remains unprofitable — a substantive headwind that can limit valuation and keep stock volatility high.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.